Inmune Bio (INMB) Assets (2017 - 2026)
Inmune Bio (INMB) recorded Assets of $26.85 million in Q2 2026, down 28.8% from $37.68 million a year earlier but up 4.0% from the prior quarter.
Powered by 
Analysis
Inmune Bio (INMB) Assets (2017 - 2026) Analysis & Trends
At the end of FY2025, Inmune Bio reported Assets of $32.35 million, down 18.2% from FY2024.
- Annual Assets has declined for four straight years, with a five-year compound annual growth rate of -4.5% (FY2020 to FY2025).
- Across earlier years, Assets came in at $39.56 million in FY2024 (-30.6%), $57 million in FY2023 (-30.3%), $81.8 million in FY2022 (-18.2%) and $99.95 million in FY2021 (+145.8%).
- Quarterly Assets has ranged from $25.82 million in Q1 2026 to $107.67 million in Q3 2021 over the past five years.
- On a year-over-year basis, Assets has declined for 16 consecutive quarters, with an average decline of 26.2% over the last eight quarters.
- Peak year-over-year performance for Assets in the last five years was growth of 151.5% in Q3 2021, against a decline of 36.8% in Q3 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $25.82 million (Q1 2026), $32.35 million (Q4 2025) and $33.36 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Inmune Bio | 55.31 Mn | -36.95 Mn | - | 26.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.85 Mn |
| Mar 31, 2026 | 25.82 Mn |
| Dec 31, 2025 | 32.35 Mn |
| Sep 30, 2025 | 33.36 Mn |
| Jun 30, 2025 | 37.68 Mn |
| Mar 31, 2025 | 37.80 Mn |
| Dec 31, 2024 | 39.56 Mn |
| Sep 30, 2024 | 52.78 Mn |
| Jun 30, 2024 | 52.45 Mn |
| Mar 31, 2024 | 46.83 Mn |
| Dec 31, 2023 | 57.00 Mn |
| Sep 30, 2023 | 62.70 Mn |
| Jun 30, 2023 | 69.72 Mn |
| Mar 31, 2023 | 73.98 Mn |
| Dec 31, 2022 | 81.80 Mn |
| Sep 30, 2022 | 83.80 Mn |
| Jun 30, 2022 | 87.81 Mn |
| Mar 31, 2022 | 94.35 Mn |
| Dec 31, 2021 | 99.95 Mn |
| Sep 30, 2021 | 107.67 Mn |
API Access
Inmune Bio Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=assets&ticker=INMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "assets", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=assets&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();